Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer

International Journal of Urology

Volumn 12, Issue 5, 2005, Pages 449-455

  Cheng, Chi Wai ^a   Chan, Siu Foon Peter ^a   Chan, Lung Wai ^a   Chan, Chi Kwok ^a   Ng, Chi Fai ^a   Cheung, Ho Yuen ^a   Chan, Shu Yin Eddie ^a   Wong, Wai Sang ^a   Lai, Fernand Mac Moune ^a   To, Ka Fai ^a   Li, Miu Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bacillus Calmette Guerin vaccine; Bladder neoplasms; Epirubicin; Transitional cell

Indexed keywords

BCG VACCINE; EPIRUBICIN;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TRANSURETHRAL RESECTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CROSS-OVER STUDIES; CYSTECTOMY; CYSTOSCOPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 22544435509     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01064.x     Document Type: Article

References (19)

1. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 2000; 163: 73-8.
2. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol. 1985; 134: 40-47.
3. Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol. 1996; 156: 1934-40.
4. Oosterlinck W, Kurth KH, Schroder F et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta,T1 papillary carcinoma of the bladder. J. Urol. 1993; 149: 749-52.
5. Melekos MD, Chionis HS, Paranychianakis GS, Dauaher HH. Intravesical 4′-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer 1993; 72: 1749-55.
6. Shinohara N, Nonomura K, Tanaka M et al. Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group. Cancer Chemother. Pharmacol. 1994; 35: S41-5.
7. van der Meijden APM, Brausi M, Zambon V et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk TA, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J. Urol. 2001; 166: 476-81.
8. De Reijke TM, Kurth KH, Hall RR, Brausi M, Morjaria U, Sylvester R. First results of a phase III study comparing BCG and epirubicin in TIS of the bladder: an EORTC GU Group study. Eur. Urol. 2001; 39: 118.
9. Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am. J. Clin. Oncol. 2003; 26: 402-407.
10. Pagano F, Bassi P, Milani C et al. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 1991; 146: 32-5.
11. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 1995; 13: 1404-1408.
12. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 1964-70.
13. Cookson MS, Herr HW, Zhang ZF et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 1997; 158: 62-7.
14. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: 1124-9.
15. Palou J, Laguna P, Millan-Rodriguez F et al. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J. Urol. 2001; 165: 1488-91.
16. Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol. 1988; 6: 1450-55.
17. Herr HW, Badalament RA, Amato DA et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J. Urol. 1989; 141: 22-9.
18. Soloway MS, Perito PE. Superficial bladder cancer: diagnosis, surveillance and treatment. J. Cell. Biochem. 1992; 161: 120-27.
19. Ali-El-Dein B, Sarhan O, Hinev A et al. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU Int. 2003; 92: 393-9.